STERIS plc (NYSE:STE) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC trimmed its position in shares of STERIS plc (NYSE:STE - Free Report) by 10.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,562 shares of the medical equipment provider's stock after selling 2,838 shares during the quarter. Orion Portfolio Solutions LLC's holdings in STERIS were worth $5,715,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Massachusetts Financial Services Co. MA grew its position in STERIS by 13.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider's stock worth $1,414,453,000 after buying an additional 778,613 shares during the period. Impax Asset Management Group plc grew its position in shares of STERIS by 29.7% in the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider's stock valued at $251,663,000 after purchasing an additional 263,383 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of STERIS by 9.5% in the third quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider's stock valued at $270,230,000 after purchasing an additional 96,336 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of STERIS by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 840,194 shares of the medical equipment provider's stock valued at $184,439,000 after purchasing an additional 95,412 shares during the last quarter. Finally, Raymond James & Associates grew its position in shares of STERIS by 1.5% in the third quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider's stock valued at $194,309,000 after purchasing an additional 12,005 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company's stock, valued at $10,603,710. This represents a 35.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares of the company's stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on STE shares. JMP Securities reiterated a "market outperform" rating and issued a $265.00 price target on shares of STERIS in a research report on Monday, November 18th. Piper Sandler upgraded shares of STERIS from a "neutral" rating to an "overweight" rating and increased their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research report on Friday, November 8th. Stephens reiterated an "overweight" rating and issued a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. Finally, StockNews.com downgraded shares of STERIS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, STERIS presently has a consensus rating of "Moderate Buy" and an average target price of $262.50.

STERIS Trading Down 0.1 %

Shares of STE traded down $0.26 on Monday, hitting $215.63. 434,424 shares of the stock traded hands, compared to its average volume of 499,481. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21.28 billion, a P/E ratio of 49.23 and a beta of 0.83. The stock's 50 day moving average is $222.40 and its two-hundred day moving average is $227.65. STERIS plc has a 1 year low of $197.82 and a 1 year high of $248.24.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts' consensus estimates of $2.12 by $0.02. The company had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS's revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.03 earnings per share. As a group, sell-side analysts predict that STERIS plc will post 9.1 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.06%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio is currently 52.05%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.